References
- Margo CE, Mulla ZD. Malignant tumors of the orbit. Analysis of the florida cancer registry. Ophthalmology. 1998;105(1):185–190. doi:https://doi.org/10.1016/S0161-6420(98)92107-8.
- Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer. 1972;29:252–260.
- Demirci H, Shields CL, Shields JA, Honavar SG, Mercado GJ, Tovilla JC. Orbital tumors in the older adult population. Ophthalmology. 2002;109(2):243–248. doi:https://doi.org/10.1016/S0161-6420(01)00932-0.
- McKelvie PA. Ocular adnexal lymphomas: a review. Adv Anat Pathol. 2010;17(4):251–261. doi:https://doi.org/10.1097/PAP.0b013e3181e4abdb.
- Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012;122(10):3416–3423. doi:https://doi.org/10.1172/JCI61272.
- Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol. 1999;36:115–127.
- Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105(11):1684–1692. doi:https://doi.org/10.1038/bjc.2011.450.
- Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724–3734. doi:https://doi.org/10.1182/blood-2010-05-282632.
- Swerdlow SH, World Health O, International Agency for Research on C. WHO classification of tumours of haematopoietic and lymphoid tissues; 2017.
- Inwards DJ, Witzig TE. Initial therapy of mantle cell lymphoma. Ther Adv Hematol. 2011;2(6):381–392. doi:https://doi.org/10.1177/2040620711412418.
- Shields CL, Lally SE, Shields JA. Mantle-cell lymphoma-taming the tiger. JAMA Ophthalmol. 2017;135(12):1374–1375. doi:https://doi.org/10.1001/jamaophthalmol.2017.4290.
- Sjo LD, Ralfkiaer E, Prause JU, Petersen JH, Madsen J, Pedersen NT, et al. Increasing incidence of ophthalmic lymphoma in Denmark from 1980 to 2005. Invest Ophthalmol Vis Sci. 2008;49(8):3283–3288. doi:https://doi.org/10.1167/iovs.08-1768.
- Ferry JA, Fung CY, Zukerberg L, Lucarelli MJ, Hasserjian RP, Preffer FI, et al. Lymphoma of the ocular adnexa: a study of 353 cases. Am J Surg Pathol. 2007;31(2):170–184. doi:https://doi.org/10.1097/01.pas.0000213350.49767.46.
- Holm F, Mikkelsen LH, Kamper P, Rasmussen PK, Larsen TS, Sjo LD, et al. Ocular adnexal lymphoma in Denmark: a nationwide study of 387 cases from 1980 to 2017. Br J Ophthalmol. 2020: bjophthalmol-2019-315637. doi:https://doi.org/10.1136/bjophthalmol-2019-315637.
- Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood. 1997;89(6):2067–2078. doi:https://doi.org/10.1182/blood.V89.6.2067.
- Graue GF, Finger PT, Maher E, Della Rocca D, Della Rocca R, Lelli GJ Jr., et al. Ocular adnexal lymphoma staging and treatment: American joint committee on cancer versus Ann Arbor. Eur J Ophthalmol. 2013;23(3):344–355. doi:https://doi.org/10.5301/ejo.5000224.
- Edge SB. American Joint Committee on Cancer. AJCC Cancer Staging Manual. Vol. xiv. 7th ed. New York: Springer; 2010:648.
- Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558–565. doi:https://doi.org/10.1182/blood-2007-06-095331.
- Hoster E, Rosenwald A, Berger F, Bernd HW, Hartmann S, Loddenkemper C, et al. Prognostic value of Ki-67 Index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European mantle cell lymphoma network. J Clin Oncol. 2016;34(12):1386–1394. doi:https://doi.org/10.1200/JCO.2015.63.8387.
- Bosch F, Lopez-Guillermo A, Campo E, Ribera JM, Conde E, Piris MA, et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer. 1998;82(3):567–575. doi:https://doi.org/10.1002/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z.
- Knudsen MKH, Rasmussen PK, Coupland SE, Esmaeli B, Finger PT, Graue GF, et al. Clinicopathological features of ocular adnexal mantle-cell lymphoma in an international multicenter cohort. JAMA Ophthalmol. 2017;135(12):1367–1374. doi:https://doi.org/10.1001/jamaophthalmol.2017.4810.
- Rasmussen P, Sjo LD, Prause JU, Ralfkiaer E, Heegaard S. Mantle cell lymphoma in the orbital and adnexal region. Br J Ophthalmol. 2009;93(8):1047–1051. doi:https://doi.org/10.1136/bjo.2008.146910.
- Olsen TG, Holm F, Mikkelsen LH, Rasmussen PK, Coupland SE, Esmaeli B, et al. Orbital lymphoma-an international multicenter retrospective study. Am J Ophthalmol. 2019;199:44–57. doi:https://doi.org/10.1016/j.ajo.2018.11.002.
- Olsen TG, Heegaard S. Orbital lymphoma. Surv Ophthalmol. 2019;64(1):45–66. doi:https://doi.org/10.1016/j.survophthal.2018.08.002.
- Knop E, Knop N. Influence of the eye-associated lymphoid tissue (EALT) on inflammatory ocular surface disease. Ocul Surf. 2005;3(4 Suppl):S180–6. doi:https://doi.org/10.1016/s1542-0124(12)70251-3.
- Rasmussen PK. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features. Acta Ophthalmol. 2013;91 Thesis 5:1–27. doi:https://doi.org/10.1111/aos.12189.
- Kumar A, Sha F, Toure A, Dogan A, Ni A, Batlevi CL, et al. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer J. 2019;9(6):50. doi:https://doi.org/10.1038/s41408-019-0209-5.
- Grillo-López AJ, White CA, Dallaire BK, Varns CL, Shen CD, Wei A, et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol. 2000;1(1):1–9. doi:https://doi.org/10.2174/1389201003379059.
- Mikkelsen L, Würtz N, Heegaard S. Recent advances in treating extra-ocular lymphomas. Expert Rev Ophthalmol. 2018;13.
- Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv62–iv71. doi:https://doi.org/10.1093/annonc/mdx223.
- Lee C, Martin P. Watch and wait in mantle cell lymphoma. Hematol Oncol Clin North Am. 2020;34(5):837–847. doi:https://doi.org/10.1016/j.hoc.2020.06.002.
- Kirkegaard MM, Rasmussen PK, Coupland SE, Esmaeli B, Finger PT, Graue GF, et al. Conjunctival lymphoma–an international multicenter retrospective study. JAMA Ophthalmol. 2016;134(4):406–414. doi:https://doi.org/10.1001/jamaophthalmol.2015.6122.
- Svendsen FH, Rasmussen PK, Coupland SE, Esmaeli B, Finger PT, Graue GF, et al. Lymphoma of the eyelid - an international multicenter retrospective study. Am J Ophthalmol. 2017;177:58–68. doi:https://doi.org/10.1016/j.ajo.2017.02.004.
- Vose JM. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2017;92(8):806–813. doi:https://doi.org/10.1002/ajh.24797.
- Hoster E, Metzner B, Forstpointner R, Pfreundschuh M, Trumper L, Hallek M, et al. Autologous stem cell transplantation and addition of rituximab independently prolong response duration in advanced stage mantle cell lymphoma. Blood. 2009;114(22):362–363. doi:https://doi.org/10.1182/blood.V114.22.880.880.